Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology-Reference-Cited by-同舟云学术

Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

Published:2014-05 Issue:3 Volume:15 Page:173-181
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Gridelli Cesare,de Marinis Filippo,Cappuzzo Federico,Di Maio Massimo,Hirsch Fred R.,Mok Tony,Morgillo Floriana,Rosell Rafael,Spigel David R.,Yang James Chih-Hsin,Ciardiello Fortunato

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference55 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group;BMJ,1995

2. New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development;Di Maio;Expert Opin Investig Drugs,2010

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci USA,2004

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor;AboutOpen;2022-10-24

2. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease;Acta Oncologica;2022-04-17

3. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer;Frontiers in Oncology;2021-05-28

4. Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases;Cancers;2020-11-14

5. Synthesis of a novel 99mTc labeled GE11 peptide for EGFR SPECT imaging;International Journal of Radiation Biology;2020-09-01